HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MOLN
Molecular Partners AG
There isn't enough reported data to score MOLN yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MOLN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
MOLN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MOLN PE Valuation
MOLN has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MOLN Forward outlook
There aren't enough analyst estimates for MOLN to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
MOLN has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus MOLN down 187%.
MOLN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$1.99 | -$0.08 |
| Q2 2025 | -$2.15 | -$0.04 |
| Q4 2024 | -$1.91 | +$0.37 |
| Q2 2024 | -$2.11 | +$0.15 |
| Q4 2023 | -$2.28 | -154% |
| Q4 2022 | $4.26 | +$6.74 |
| Q4 2021 | -$2.48 | +$0.65 |
| Q4 2020 | -$3.13 | -$1.08 |
MOLN is still losing money, but less than at its worst: $1.99 per share over the past year, against $3.13 at its worst in late 2020.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the stronger quarterly revenue trend. Revenue is up 49% for HIMS versus down 100% for MOLN.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
MOLN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $819.8K | -81% |
| Q2 2024 | $5.2M | +24% |
| Q4 2023 | $4.3M | -29% |
| Q2 2023 | $4.2M | -98% |
| Q4 2022 | $6.1M | -48% |
| Q4 2021 | $11.7M | +531% |
| Q4 2020 | $1.9M | -55% |
| Q3 2020 | $340.7K | -92% |
MOLN's revenue has slid since its 2022 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -4315% | -3729 points |
| Q2 2024 | -742% | -822 points |
| Q4 2023 | -843% | -193 points |
| Q2 2023 | -894% | +405 points |
| Q4 2022 | -586% | +4775 points |
| Q2 2022 | 79% | +372 points |
| Q4 2021 | -650% | -329 points |
| Q4 2020 | -1299% | -944 points |
MOLN's operating margin was −4315% last quarter, down 3729 points from the same quarter a year ago, near the bottom of its range since 2016.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the stronger cash trend. Its trailing FCF is down 84% versus its history, compared with MOLN at down 283%.
MOLN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$25.6M | +$6.8M |
| Q2 2025 | -$37M | +$2.8M |
| Q4 2024 | -$32.3M | +$3.3M |
| Q2 2024 | -$39.8M | -$3.7M |
| Q4 2023 | -$35.6M | +$4.3M |
| Q2 2023 | -$36.1M | -120% |
| Q4 2022 | -$39.9M | +$70.7M |
| Q4 2021 | -$110.6M | -4638% |
MOLN has burned cash in most quarters: −$135M over the past year, against $70M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MOLN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MOLN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +136K shares |
| 1 year | +14% | +4.5M shares |
| 3 years | +72% | +15.6M shares |
| 5 years | +77% | +16.2M shares |
| Available history | +84% | +17M shares |
MOLN has 37M diluted shares, up 14% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
| Q2 2019 | — |
| Q1 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MOLN Net Leverage
MOLN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MOLN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.2 | Neutral |
| Stochastic | 4.6 | Oversold |
MOLN's weekly RSI is 30 (neutral) and its Stochastic is 5 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MOLN PE vs Healthcare Sector
| Metric | MOLN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MOLN has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MOLN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.64 | 17% below |
| 20 week MA | $3.94 | 24% below |
| 50 week MA | $4.15 | 27% below |
| 100 week MA | $4.15 | 27% below |
| 200 week MA | $4.79 | 37% below |
MOLN is in a downtrend: it's below all five of its weekly moving averages, and 37% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
MOLN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $19.3 | $20.2 | +4.9% |
| 2022 | $20.2 | $6.55 | -68% |
| 2023 | $6.55 | $4.18 | -36% |
| 2024 | $4.18 | $5.30 | +27% |
| 2025 | $5.30 | $4.23 | -20% |
| 2026 YTD | $4.23 | $3.01 | -29% |
MOLN has the edge over HIMS on returns for 2026, with the stronger performance.